Overview of Post-approval Submissions Management in US, Europe and Canada
Abstract
In today’s business era & competition in pharmaceutical industries, post-approval evaluation & cGMP compliance plays an important role. Regulatory approval is a critical milestone in the lifecycle of pharmaceuticals and medical devices, ensuring their safety, efficacy, and quality before entering the market. A regulatory affair is a bridge between pharma industry and health authorities.
Post-Approval function in Regulatory Affairs department plays a major role in supporting continuous commercialization and facilitating for its implementation. This function are responsible to provide strategic regulatory inputs to plant team on their proposals and to facilitate smooth submission followed by acceptance/ approval. In the USA, the Food and Drug Administration (FDA) governs the regulatory process, employing a thorough and well-defined approach to submission evaluation. Europe, with the European Medicines Agency (EMA) at its helm, utilizes a centralized procedure for marketing authorization, harmonizing regulations across member states. Meanwhile, Health Canada oversees regulatory activities in Canada, emphasizing a risk-based approach to ensure public safety.
Post-approval submission management is equally vital in maintaining compliance and ensuring ongoing product safety. This paper delves into the strategies and best practices for handling post-approval changes, variations, and renewals. It examines the role of regulatory intelligence, life cycle management, and effective communication with regulatory agencies to navigate the evolving regulatory landscape.
By comparing and contrasting the regulatory processes in the USA, Europe and Canada, this overview aims to provide valuable insights for pharmaceutical and medical device companies seeking global market access. Understanding the intricacies of regulatory submission and post-approval submission management across these regions is essential for successful product development, commercialisation and long-term regulatory compliance.
Downloads
References
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
